- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT05279703
Epinephrine Infusion for Prophylaxis Against Maternal Hypotension During Cesarean Delivery
The Use of Epinephrine Infusion for Prophylaxis Against Maternal Hypotension During Cesarean Delivery: a Randomized Controlled Dose-finding Trial
Maternal hypotension after spinal block is a common complication after subarachnoid block in this population. The incidence of maternal hypotension is nearly 60% when prophylactic vasopressors are not used. Therefore, it is highly recommended to use vasopressors, preferably as continuous infusion, for prophylaxis rather than delaying their use until hypotension occurs.
Phenylephrine (PE) is the recommended drug for prophylaxis against hypotension during cesarean delivery; however, the use of PE is commonly associated with decreased heart rate and probably cardiac output because PE is a pure alpha adrenoreceptor agonist. Introduction of NE in obstetric practice had shown favorable maternal and neonatal outcomes and was associated with higher heart rate and cardiac output compared to PE. However, there is still some mothers who develop bradycardia and diminished cardiac output with the use of NE. The most desired scenario during hemodynamic management of mothers during cesarean delivery would achieve the least possible incidences of maternal hypotension, bradycardia and reactive hypertension. Therefore, it is warranted to reach a vasopressor regimen with the most stable hemodynamic profile.
In the last year, epinephrine was reported for the first time in obstetric practice with acceptable safety on the mother and the fetus. However, there is still lack of data about the most appropriate dose for infusion during cesarean delivery. This study aims to compare three prophylactic infusion rates for epinephrine during cesarean delivery.
Panoramica dello studio
Stato
Condizioni
Intervento / Trattamento
Descrizione dettagliata
Upon arrival to the operating room, the patient will be in supine position with left uterine displacement using a wedge below the right buttock. Routine monitoring will be applied (electrocardiography, pulse oximetry, and non-invasive blood pressure monitor). An 18G-cannula will be inserted, and the patients will receive 10 mg metoclopramide. Baseline heart rate and systolic blood pressure will be recorded as the average of three consecutive readings with 2-minutes interval.
Lactated Ringer's solution will be infused at rate of 15 mL/Kg over 10 minutes as a co-load; spinal anesthesia will be achieved by injecting 10 mg of hyperbaric bupivacaine and 20 mcg fentanyl into the subarachnoid space at L3-L4 or L4-L5 interspace using 25G spinal needle.
After subarachnoid block, mothers will be placed in supine position with left-lateral tilt and the vasopressor infusion will be started.
- 0.01 mcg group
- 0.02 mcg group
- 0.03 mcg group The vasopressor infusion will be through the same line as the fluid a three-way stopcock. The vasopressor infusion will be stopped if heart rate became ≥130% of baseline or systolic blood pressure ≥120% of baseline, otherwise the infusion will be stopped 5 minutes after delivery of the baby.
Block success will be assessed after 5 minutes from intrathecal injection of local anesthetic; and will be confirmed if sensory block level is at T4.
Post-spinal hypotension (defined as systolic blood pressure ≤80% of the baseline reading during the period from intrathecal injection to delivery of the fetus) will be managed by administration of 9 mg of ephedrine Severe post-spinal hypotension (defined as systolic blood pressure ≤60% of the baseline reading during the period from intrathecal injection to delivery of the fetus) will be managed by administration IV ephedrine 15 mg.
Reactive hypertension (defined as systolic blood pressure ≥120% of the baseline reading) will be managed by stoppage of the infusion till the next systolic blood pressure reading. The infusion will be then re-started at the half of the initial rate, when systolic blood pressure decreases to be within 20% of the baseline reading.
Intraoperative bradycardia (defined as heart rate less than 55 bpm) will be managed by IV atropine bolus (0.5 mg) will be administered.
Fluid administration will be continued up to a maximum of 1.5 liters. An oxytocin bolus (0.5 IU) will be delivered over five seconds after delivery the infused at a rate of 2.5 IU/hour.
Tipo di studio
Iscrizione (Anticipato)
Fase
- Fase 4
Contatti e Sedi
Contatto studio
- Nome: ahmed hasanin
- Numero di telefono: 01095076954
- Email: ahmedmohamedhasanin@gmail.com
Luoghi di studio
-
-
-
Cairo, Egitto, 11562
- Reclutamento
- Kasr Alaini Hospital
-
Contatto:
- Anesthesia, Pain Management and Surgical ICU Department
- Numero di telefono: 00201222224057
- Email: Anesthesia.kasralainy@gmail.com
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- full-term singleton pregnant women
- American society of anesthesiologist-physical status I or II,
- scheduled for elective cesarean delivery
Exclusion Criteria:
- Patients with uncontrolled cardiac morbidities (patients with tight valvular lesion, impaired contractility with ejection fraction < 50%, heart block, and arrhythmias),
- hypertensive disorders of pregnancy,
- peripartum bleeding,
- coagulation disorders (patients with INR >1.4 and or platelet count < 80000 /dL) or
- any contraindication to regional anesthesia,
- and baseline systolic blood pressure (SBP) < 100 mmHg
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Prevenzione
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Quadruplicare
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
---|---|
Comparatore attivo: 0.03 mcg group
epinephrine infusion will be started after subarachnoid block until 5 minutes after delivery of the baby
|
epinephrine infusion rate of 0.03 mcg/kg/min
Altri nomi:
|
Comparatore attivo: 0.02 mcg group
epinephrine infusion will be started after subarachnoid block until 5 minutes after delivery of the baby
|
epinephrine infusion rate of 0.02 mcg/kg/min
Altri nomi:
|
Comparatore attivo: 0.01 mcg group
epinephrine infusion will be started after subarachnoid block until 5 minutes after delivery of the baby
|
epinephrine infusion rate of 0.01 mcg/kg/min
Altri nomi:
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
---|---|---|
incidence of postspinal hypotension
Lasso di tempo: 1 minute after subarachnoid injection till 5 minutes after baby delivery
|
systolic blood pressure ≤80% of the baseline reading
|
1 minute after subarachnoid injection till 5 minutes after baby delivery
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
---|---|---|
incidence of tachycardia
Lasso di tempo: 1 minute after subarachnoid injection till 5 minutes after baby delivery
|
heart rate > 130% of baseline
|
1 minute after subarachnoid injection till 5 minutes after baby delivery
|
incidence of hypertension
Lasso di tempo: 1 minute after subarachnoid injection till 5 minutes after baby delivery
|
systolic blood pressure >120% of baseline
|
1 minute after subarachnoid injection till 5 minutes after baby delivery
|
incidence of severe hypotension
Lasso di tempo: 1 minute after subarachnoid injection till 5 minutes after baby delivery
|
systolic blood pressure ≤60% of the baseline reading
|
1 minute after subarachnoid injection till 5 minutes after baby delivery
|
mean heart rate
Lasso di tempo: 1 minute after subarachnoid injection, every 2 minutes during procedure, till 5 minutes after baby delivery
|
beat per minute
|
1 minute after subarachnoid injection, every 2 minutes during procedure, till 5 minutes after baby delivery
|
mean systolic blood pressure
Lasso di tempo: 1 minute after subarachnoid injection, every 2 minutes during procedure, till 5 minutes after baby delivery
|
mmHg
|
1 minute after subarachnoid injection, every 2 minutes during procedure, till 5 minutes after baby delivery
|
total ephedrine requirement
Lasso di tempo: 1 minute after subarachnoid injection till 5 minutes after baby delivery
|
mg
|
1 minute after subarachnoid injection till 5 minutes after baby delivery
|
total atropine requirement
Lasso di tempo: 1 minute after subarachnoid injection till 5 minutes after baby delivery
|
mg
|
1 minute after subarachnoid injection till 5 minutes after baby delivery
|
Apgar score
Lasso di tempo: 5 minutes after delivery
|
Breathing effort Heart rate Muscle tone Reflexes Skin color Each category is scored with 0, 1, or 2, depending on the observed condition
|
5 minutes after delivery
|
umbilical blood pH
Lasso di tempo: 5 minutes after delivery
|
pH
|
5 minutes after delivery
|
umbilical blood PCO2
Lasso di tempo: 5 minutes after delivery
|
mmHg
|
5 minutes after delivery
|
umbilical blood PO2
Lasso di tempo: 5 minutes after delivery
|
mmHg
|
5 minutes after delivery
|
umbilical blood HCO3
Lasso di tempo: 5 minutes after delivery
|
mmol/L
|
5 minutes after delivery
|
Collaboratori e investigatori
Sponsor
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Completamento primario (Anticipato)
Completamento dello studio (Anticipato)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Termini MeSH pertinenti aggiuntivi
- Malattia cardiovascolare
- Malattie vascolari
- Ipotensione
- Effetti fisiologici delle droghe
- Agenti adrenergici
- Agenti neurotrasmettitori
- Meccanismi molecolari dell'azione farmacologica
- Agenti autonomi
- Agenti del sistema nervoso periferico
- Alfa-agonisti adrenergici
- Agonisti adrenergici
- Agenti broncodilatatori
- Agenti antiasmatici
- Agenti del sistema respiratorio
- Beta-agonisti adrenergici
- Simpaticomimetici
- Agenti vasocostrittori
- Midriatici
- Epinefrina
- Racepinefrina
- Borato di adrenalina
Altri numeri di identificazione dello studio
- MD-399-2021
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Descrizione del piano IPD
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .
Prove cliniche su Epinephrine 0.03
-
Bp Consulting, IncCompletato
-
Florida Atlantic UniversityAdvanced Diabetes Treatment CentersTerminatoDiabete | La guarigione delle feriteStati Uniti
-
Assiut UniversityCompletato
-
University of MiamiCompletato
-
Alcon ResearchCompletatoIpertensione oculare | Glaucoma ad angolo aperto
-
Hospices Civils de LyonCompletato
-
National Cancer Institute (NCI)Attivo, non reclutanteNeoplasia solida dell'adultoStati Uniti
-
Ain Shams UniversityNational Hepatology & Tropical Medicine Research InstituteCompletato